Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study

Mei Feng, Aili Lu, Hongxia Gao, Caiwen Qian, Jun Zhang, Tongxiang Lin, Yuanqi Zhao, Mei Feng, Aili Lu, Hongxia Gao, Caiwen Qian, Jun Zhang, Tongxiang Lin, Yuanqi Zhao

Abstract

This retrospective study aimed to assess the safety of patients with severe cerebral palsy (CP), who received allogeneic umbilical cord blood stem cells (UCBSCs) treatment from August 2009 to December 2012 in Guangdong Provincial Hospital of Chinese Medicine. A total of 47 patients with average age of 5.85 ± 6.12 years were evaluated in this study. There was no significant association with allogeneic UCBSCs treatments found in the data of the laboratory index . No casualties occurred. Some adverse events during treatments were found in 26 (55.3%) patients, including fever (42.6%) and vomiting (21.2%). Intrathecal infusion and the ages at the initiation of treatment (≤10 years old) were risk factors for the occurrence of adverse events by logistic regression analysis. However, all adverse events disappeared after symptomatic treatment. No treatment related serious adverse events were found in follow-up visits within 6 months. In conclusion, allogeneic UCBSCs treatment was relatively safe for severe CP patients.

References

    1. Rosenbaum P., Paneth N., Leviton A., Goldstein M., Bax M. A report: the definition and classification of cerebral palsy April 2006. Developmental Medicine and Child Neurology. Supplement. 2007;109(2):8–14.
    1. Blair E., Watson L. Epidemiology of cerebral palsy. Seminars in Fetal and Neonatal Medicine. 2006;11(2):117–125. doi: 10.1016/j.siny.2005.10.010.
    1. El-Tallawy H., Farghaly W., Shehata G., et al. Cerebral palsy in Al-Quseir City, Egypt: prevalence, subtypes, and risk factors. Neuropsychiatric Disease and Treatment. 2014;10:1267–1272. doi: 10.2147/ndt.s59599.
    1. Patel D. R., Greydanus D. E., Calles J. L., Jr., Pratt H. D. Developmental disabilities across the lifespan. Disease-a-Month. 2010;56(6):305–397. doi: 10.1016/j.disamonth.2010.02.001.
    1. Luan Z., Liu W., Qu S., et al. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplantation. 2012;21(supplement 1):S91–S98. doi: 10.3727/096368912X633806.
    1. Moon J.-H., Kim M. J., Song S.-Y., et al. Safety and efficacy of G-CSF mobilization and collection of autologous peripheral blood stem cells in children with cerebral palsy. Transfusion and Apheresis Science. 2013;49(3):516–521. doi: 10.1016/j.transci.2013.08.003.
    1. Lee M. W., Jang I. K., Yoo K. H., Sung K. W., Koo H. H. Stem and progenitor cells in human umbilical cord blood. International Journal of Hematology. 2010;92(1):45–51. doi: 10.1007/s12185-010-0619-4.
    1. Park D.-H., Lee J.-H., Borlongan C. V., Sanberg P. R., Chung Y.-G., Cho T.-H. Transplantation of umbilical cord blood stem cells for treating spinal cord injury. Stem Cell Reviews and Reports. 2011;7(1):181–194. doi: 10.1007/s12015-010-9163-0.
    1. Park D.-H., Borlongan C. V., Willing A. E., et al. Human umbilical cord blood cell grafts for brain ischemia. Cell Transplantation. 2009;18(9):985–998. doi: 10.3727/096368909X471279.
    1. Bae S. H., Kong T. H., Lee H. S., et al. Long-lasting paracrine effects of human cord blood cells on damaged neocortex in an animal model of cerebral palsy. Cell Transplantation. 2012;21(11):2497–2515. doi: 10.3727/096368912x640457.
    1. Min K., Song J., Kang J. Y., et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013;31(3):581–591. doi: 10.1002/stem.1304.
    1. Crompton K. E., Elwood N., Kirkland M., Clark P., Novak I., Reddihough D. Feasibility of trialling cord blood stem cell treatments for cerebral palsy in Australia. Journal of Paediatrics and Child Health. 2014;50(7):540–544. doi: 10.1111/jpc.12618.
    1. Lee M., Jeong S. Y., Ha J., et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo . Biochemical and Biophysical Research Communications. 2014;446(4):983–989. doi: 10.1016/j.bbrc.2014.03.051.
    1. Carroll J. E., Mays R. W. Update on stem cell therapy for cerebral palsy. Expert Opinion on Biological Therapy. 2011;11(4):463–471. doi: 10.1517/14712598.2011.557060.
    1. Feng M., Gao H. X., Dai X. P., et al. Clinical observation on the efficacy of umbilical blood stem cells transplantation in 30 cases with severe cerebral palsy. Chinese Journal of Blood Transfusion. 2011;24(7):602–604.
    1. Palisano R., Rosenbaum P., Walter S., Russell D., Wood E., Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology. 1997;39(4):214–223.
    1. Erices A., Conget P., Minguell J. J. Mesenchymal progenitor cells in human umbilical cord blood. British Journal of Haematology. 2000;109(1):235–242. doi: 10.1046/j.1365-2141.2000.01986.x.
    1. Nieda M., Nicol A., Denning-Kendall P., Sweetenham J., Bradley B., Hows J. Endothelial cell precursors are normal components of human umbilical cord blood. British Journal of Haematology. 1997;98(3):775–777. doi: 10.1046/j.1365-2141.1997.2583074.x.
    1. Forraz N., Mcguckin C. P. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Proliferation. 2011;44(supplement 1):60–69. doi: 10.1111/j.1365-2184.2010.00729.x.
    1. McGuckin C. P., Forraz N., Allouard Q., Pettengell R. Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro. Experimental Cell Research. 2004;295(2):350–359. doi: 10.1016/j.yexcr.2003.12.028.
    1. Jensen A., Hamelmann E. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest—individual treatment with cord blood. Case Reports in Transplantation. 2013;2013:6. doi: 10.1155/2013/951827.951827
    1. Bae S. H., Lee H. S., Kang M. S., Strupp B. J., Chopp M., Moon J. The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. International Journal of Stem Cells. 2012;5(1):31–38. doi: 10.15283/ijsc.2012.5.1.31.
    1. Kurtzberg J. Update on umbilical cord blood transplantation. Current Opinion in Pediatrics. 2009;21(1):22–29. doi: 10.1097/mop.0b013e32832130bc.
    1. Reddi A. S., Kuppasani K., Ende N. Human umbilical cord blood as an emerging stem cell therapy for diabetes mellitus. Current Stem Cell Research and Therapy. 2010;5(4):356–361. doi: 10.2174/157488810793351668.
    1. Yang W.-Z., Zhang Y., Wu F., et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. Journal of Translational Medicine. 2010;8, article 75 doi: 10.1186/1479-5876-8-75.
    1. Zhang L. X., Xing L. H., Zhang L. L., et al. Clinical safety of umbilical cord blood stem cells for treatment of children with cerebral palsy. Chinese General Practice. 2010;13(68):1868–1870.
    1. Kovac A. L. Management of postoperative nausea and vomiting in children. Pediatric Drugs. 2007;9(1):47–69. doi: 10.2165/00148581-200709010-00005.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren